

D1  
2b  
2' 4

(a) comprises at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 1 and at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 2;

(b) is capable of inducing proliferation of T-cell clones specific to each of said T-cell epitope peptides; and

(c) is capable of dose-dependently inducing proliferation of peripheral lymphocytes from a cedar pollinosis patient.

D2

Claim 4 (Amended):

The peptide-based immunotherapeutic agent of claim 1, further comprising a site that is cleaved *in vivo*.

Claim 5 (Amended):

The peptide-based immunotherapeutic agent of claim 4, wherein said site is an arginine or lysine dimer.

D3

Claim 6 (Amended):

The peptide-based immunotherapeutic agent of claim 1, wherein said polypeptide contains the amino acid sequence of SEQ ID NOs: 1, 2, or 3 or immunostimulatory fragments of SEQ ID NOs: 1, 2, or 3. ~~Arg~~

Claim 13 (Amended):

D4 Mr  
The peptide-based immunotherapeutic agent according to claim 1, wherein each of said T-cell epitopes consists of minimum core sequences that stimulate T-cell proliferation.

✓ ✓ ✓ ✓ ✓ ✓  
Please cancel claims 3, 7-12, 14-16, and 18-30.

Please add the following new claims:

Rule 1.126  
31/49. The peptide-based immunotherapeutic agent of claim 1, wherein each of said T-cell epitope peptides contains no cysteine residue.

D5  
32/50. The peptide-based immunotherapeutic agent of claim 1, wherein said polypeptide molecule comprises at least one T-cell epitope peptide restricted by HLA class II DR molecule, at least one T-cell epitope peptide restricted by HLA class II DQ molecule, and at least one T-cell epitope peptide restricted by HLA class II DP molecule.

33/51. The peptide-based immunotherapeutic agent of claim 32, wherein said DR molecule is DRB5\*0101, DRB4\*0101, DRB1\*0901, or DRB1\*1501, said DQ molecule is DQA1\*0102-DQB1\*0602, and said DP molecule is DPA1\*0101-DPB1\*0501, DPA1\*0202-DPB1\*0501, or DPA1\*0101-DPB1\*0201.

34/52. The peptide-based immunotherapeutic agent of claim 32, wherein said polypeptide molecule consists of the amino acid sequence described in SEQ ID NO:1.

35/53. A method for treating or preventing the incidence of cedar pollinosis, the method comprising administering an effective amount of a peptide-based immunotherapeutic agent comprising a linear polypeptide molecule, wherein said polypeptide:

(a) comprises at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 1 and at least two T-cell epitope peptides derived from cedar pollen allergen Cry j 2;

(b) is capable of inducing proliferation of T-cell clones specific to each of said T-cell epitope peptides; and

(c) is capable of dose-dependently inducing proliferation of peripheral lymphocytes from a cedar pollinosis patient.

Full 1.126  
36 54. The method of claim <sup>35</sup>53, wherein said peptide-based immunotherapeutic agent further comprises a site that is cleaved *in vivo*.

37 55. The method of claim <sup>36</sup>54, wherein said site is an arginine or lysine dimer.

38 56. The method of claim <sup>35</sup>53, wherein said T-cell epitope peptides contain no cysteine residues.

39 57. The method of claim <sup>35</sup>53, wherein said polypeptide contains the amino acid sequence of SEQ ID NOs:1, 2, or 3, or immunostimulatory fragments of SEQ ID NOs:1, 2, or 3.

D5  
40 58. The method of claim <sup>35</sup>53, wherein said polypeptide molecule comprises at least one T-cell epitope peptide restricted by HLA class II DR molecule, at least one T-cell epitope peptide restricted by HLA class II DQ molecule, and at least one T-cell epitope peptide restricted by HLA class II DP molecule.

41 59. The method of claim <sup>40</sup>58, wherein said DR molecule is DRB5\*0101, DRB4\*0101, DRB1\*0901, or DRB1\*1501, said DQ molecule is DQA1\*0102-DQB1\*0602, and said DP molecule is DPA1\*0101-DPB1\*0501, DPA1\*0202-DPB1\*0501, or DPA1\*0101-DPB1\*0201.

42 60. The method of claim <sup>40</sup>58, wherein polypeptide molecule consists of the amino acid sequence described in SEQ ID NO:1.

43 61. The method of claim <sup>40</sup>53, wherein each of said T-cell epitope peptides consists of minimum core sequences which stimulate T-cell proliferation.

44 62. The method of claim <sup>43</sup>61, wherein said core sequence is SEQ ID NO:7.

45 63. The method of claim <sup>35</sup>53, wherein said T-cell epitope peptides are analog peptides in which one or more amino acids of the T-cell epitope peptides are substituted.

Rule 1.128

<sup>46</sup><sub>64.</sub> The method of claim <sup>45</sup>~~63~~, wherein said analog peptide has the amino acid sequence of SEQ ID NO:14.

D5 <sup>47</sup><sub>65.</sub> The method of claim <sup>35</sup>~~53~~, which further comprises a pharmaceutically acceptable carrier or diluent.

<sup>48</sup><sub>66.</sub> The peptide-based immunotherapeutic agent of claim 1, wherein said T-cell epitope peptides are analog peptides in which one or more amino acids of the T-cell epitope peptides are substituted.